Mersana Therapeutics has begun a Phase Ib extension study to evaluate its lead cancer product, XMT-1001, as a treatment for second-line gastric cancer and second-line and third-line non-small cell lung cancer.
The study will be conducted at ten clinical centres in the US.
The Phase Ib study follows the successful completion of a 74-patient Phase I clinical trial, which showed high and prolonged plasma levels of XMT-1001 active release products.
The study showed a safety profile free of the toxicities normally associated with topoisomerase I inhibitors, such as haemorrhagic cystitis and diarrhoea.
In addition, XMT-1001 demonstrated clinical activity, including tumour shrinkage and prolonged stable disease, in a heavily pre-treated patient population.
XMT-1001 is a novel DNA topoisomerase I inhibitor based on Mersana’s Fleximer polymer conjugate platform.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData